160 related articles for article (PubMed ID: 20660540)
1. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study.
Allais G; Bussone G; D'Andrea G; Moschiano F; d'Onofrio F; Valguarnera F; Manzoni GC; Grazzi L; Allais R; Benedetto C; Acuto G
Cephalalgia; 2011 Jan; 31(2):144-51. PubMed ID: 20660540
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines.
Diamond ML; Cady RK; Mao L; Biondi DM; Finlayson G; Greenberg SJ; Wright P
Headache; 2008 Feb; 48(2):248-58. PubMed ID: 18234046
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial.
Linder SL; Mathew NT; Cady RK; Finlayson G; Ishkanian G; Lewis DW
Headache; 2008 Oct; 48(9):1326-36. PubMed ID: 18484981
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.
Mannix LK; Savani N; Landy S; Valade D; Shackelford S; Ames MH; Jones MW
Headache; 2007; 47(7):1037-49. PubMed ID: 17635595
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
[TBL] [Abstract][Full Text] [Related]
6. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine.
Mathew NT;
Headache; 2002 Jan; 42(1):32-40. PubMed ID: 12005273
[TBL] [Abstract][Full Text] [Related]
7. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.
Tuchman M; Hee A; Emeribe U; Silberstein S
CNS Drugs; 2006; 20(12):1019-26. PubMed ID: 17140280
[TBL] [Abstract][Full Text] [Related]
9. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine.
Brandes JL; Smith T; Diamond M; Ames MH
Headache; 2007 Jun; 47(6):886-94. PubMed ID: 17578540
[TBL] [Abstract][Full Text] [Related]
10. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy.
Láinez MJ; Galván J; Heras J; Vila C
Eur J Neurol; 2007 Mar; 14(3):269-75. PubMed ID: 17355546
[TBL] [Abstract][Full Text] [Related]
11. Almotriptan increases pain-free status in patients with acute migraine treated in placebo-controlled clinical trials.
Mathew NT
Headache; 2002 Jan; 42 Suppl 1():32-7. PubMed ID: 11966862
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study.
Cabarrocas X;
Clin Ther; 2001 Nov; 23(11):1867-75. PubMed ID: 11768838
[TBL] [Abstract][Full Text] [Related]
13. Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study.
Bartolini M; Giamberardino MA; Lisotto C; Martelletti P; Moscato D; Panascia B; Savi L; Pini LA; Sances G; Santoro P; Zanchin G; Omboni S; Ferrari MD; Fierro B; Brighina F
J Headache Pain; 2012 Jul; 13(5):401-6. PubMed ID: 22592864
[TBL] [Abstract][Full Text] [Related]
14. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial.
Dowson AJ; Massiou H; Laínez JM; Cabarrocas X
Cephalalgia; 2002 Jul; 22(6):453-61. PubMed ID: 12133045
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan.
Savi L; Omboni S; Lisotto C; Zanchin G; Ferrari MD; Zava D; Pinessi L
J Headache Pain; 2011 Dec; 12(6):609-15. PubMed ID: 21842274
[TBL] [Abstract][Full Text] [Related]
16. Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis.
Cady R
Headache; 2002 Jan; 42 Suppl 1():26-31. PubMed ID: 11966861
[TBL] [Abstract][Full Text] [Related]
17. Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
Dowson AJ; Massiou H; Lainez JM; Cabarrocas X
Headache; 2004 Apr; 44(4):318-22. PubMed ID: 15109355
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study.
Loder E; Silberstein SD; Abu-Shakra S; Mueller L; Smith T
Headache; 2004 Feb; 44(2):120-30. PubMed ID: 14756849
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine.
Bartolini M; Giamberardino MA; Lisotto C; Martelletti P; Moscato D; Panascia B; Savi L; Pini LA; Sances G; Santoro P; Zanchin G; Omboni S; Ferrari MD; Brighina F; Fierro B
J Headache Pain; 2011 Jun; 12(3):361-8. PubMed ID: 21437714
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
